SCHEMBL3109645

SCHEMBL3109645

CC(Oc1ccc2nc(N)sc2c1)c1c(Cl)ccc(Cl)c1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.53
CYP1A2 P05177 2/20 0.53
CYP2C19 P33261 1/20 0.53
CYP2D6 P10635 1/20 0.51
TP53 P04637 3/20 0.50
HSD17B10 Q99714 2/20 0.50
ALDH1A1 P00352 1/20 0.50
TSHR P16473 1/20 0.50
MET P08581 8/20 0.47
KDR P35968 6/20 0.47
SRC P12931 3/20 0.47
FGFR2 P21802 3/20 0.47
AXL P30530 3/20 0.47
FLT3 P36888 3/20 0.47
MST1R Q04912 3/20 0.47
KIT P10721 2/20 0.47
RAB9A P51151 5/20 0.47
NPC1 O15118 4/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
SCN4A P35499 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3104578 0.91 MET (0.49) CYP3A4CYP1A2CYP2C19CYP2D6TP53
SCHEMBL3094263 0.91 MET (0.60) CYP3A4CYP1A2CYP2C19CYP2D6MET
SCHEMBL3102102 0.89 CYP3A4 (0.55) CYP3A4CYP1A2CYP2C19CYP2D6TP53
SCHEMBL3112523 0.84 CYP3A4 (0.49) CYP3A4CYP1A2CYP2C19CYP2D6TP53
SCHEMBL3093043 0.81 CYP3A4 (0.48) CYP3A4CYP1A2CYP2C19CYP2D6TP53
SCHEMBL3097904 0.80 MET (0.46) METKDRSRCFGFR2AXL
SCHEMBL3102178 0.80 CYP3A4 (0.56) CYP3A4CYP1A2CYP2C19CYP2D6TP53
SCHEMBL3655253 0.80 ATAD2 (0.52) CYP3A4CYP1A2CYP2C19TP53RAB9A
SCHEMBL3099104 0.79 CYP3A4 (0.55) CYP3A4CYP1A2CYP2C19TP53HSD17B10
SCHEMBL3104841 0.79 MET (0.46) ALDH1A1METKDRSRCFGFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188078-B2 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors SANOFI-AVENTIS (FR) 2012-05-29 US disclosed
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS SANOFI-AVENTIS (FR) 2010-10-28 US disclosed
EP-2205568-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS Sanofi-Aventis (FR) 2010-07-14 EP disclosed
WO-2009087305-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS SANOFI-AVENTIS (FR) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100273793-A1 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS MET, ALK, JAK2 CYP3A4 324/4885CYP1A2 935/4885CYP2C19 182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.